



Sanofi Innovation Awards iAwards

Sanofi iAwards: Call-for-Proposals

9UWV 'gY`YVWYX`J5k UfX`dfc`YVWk`J`'fYVW`j` Y.

- AFGI ECCCÁ^ ^æ&@Á } ää * ÁQ &` ää * Á. cá cá } æÁ äá^&@Á. • DÁ | ÁGÁ [] c@
- Úæ [-Á &á } cãÁ c` ^ | c` Á^ áãæ` áÁ | [b &Á æ æ ^ { ^ } ó ~] [| óæ á ÁÁ &á } cãÁ &@æ] á }
- QË ä áÁ^ [~ | &• Á ~ &@æ Á^ æ ^ } • É [| & {] [~ } á • É &ÉÁ^ { ^ áÁ^ &•• æ^ Á Áãçæ & Á @ Á | [b &c
- Û` &&•• ~ | Á | [b &@ & | ~ | áÁ^ & | } ç^ | c` áÁ ÁÜÖ Áæ áÁ^ & á^ Áæ ááá } æÁ } ää * Á | ÁGÁ^ æ•

Areas of Interest

Sanofi is seeking the following type of opportunities in the therapeutic areas provided below:

- Early stage compounds, small molecules or biologics targeting novel disease mechanisms
- Disease relevant targets with validated mechanism of action
- Technology platforms with the potential to significantly improve drug discovery and development (examples – gene therapy, biologics development)
- Novel therapeutic modalities

■ IMMUNOLOGY & INFLAMMATION

- Diseases associated with dysregulated Type 2 immune responses including Atopic Dermatitis and Asthma
- Type 1/17 immune responses and Rheumatological disorders including Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Lupus Erythematosus, and IBD
- Autoimmune sequelae of checkpoint inhibition
- Co-stimulation and co- inhibitory pathways in autoimmune and allergic diseases
- Immune tolerance, organ-specific autoimmunity and emerging immunotherapies for autoimmune disease.
- Systems and computational immunology
- Immuno-metabolism

■ IMMUNO-ONCOLOGY

- Mechanisms of innate and acquired resistance to checkpoint blockade
- Immuno-modulatory function of CD38
- Immuno-modulatory function of TGFb
- Immune cell engagers (NK cells & T cells engagers)
- Immuno-conjugates
- Novel ADC targets
- Intra-tumoral Treg depletion, modulation of immunosuppressive myeloid lineages
- Immune profiling methodologies in preclinical and clinical setting
- Novel translational models in IO

■ MOLECULAR ONCOLOGY

Sanofi priority indications are breast, lung, multiple myeloma, prostate but also could be other cancers pending on target or modality

- Novel targets and/or early drug discovery projects in molecularly-defined cancer populations and/or lineage
- Tumor induced immune-suppression: regulation of anti-tumor immunity when the target is located in tumor cells
- Tumors microenvironment targeting programs
- Modality: targeted protein degradation (PROTAC, Glue, monovalent degrader)

The deadline for submission is
June 3rd, 2020